Seasonal influenza-RSV combined vaccine and preparation method and application thereof

One-RSV and combined vaccine technology, applied in biochemical equipment and methods, vaccines, multivalent vaccines, etc., can solve the problems of lack of mastery of VLP technology, limited VLP production, repeated infection of patients, etc., and achieve the expansion of vaccination population and vaccination The scope and vaccination method are simple and efficient, and the effect of less adverse reactions

Active Publication Date: 2018-04-27
BRAVOVAX
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In 2009, the SandbulteMR research team used virus-like particles (VLP) containing only influenza virus NA for the detection of anti-NA antibodies. This method has applied for a patent. Due to the limited yield of the prepared VLP, there may also be baculovirus in the system. It is difficult for laboratories or vaccine manufacturers who lack VLP technology to carry out
[0025] Further research b

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Seasonal influenza-RSV combined vaccine and preparation method and application thereof
  • Seasonal influenza-RSV combined vaccine and preparation method and application thereof
  • Seasonal influenza-RSV combined vaccine and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0051] Below in conjunction with embodiment the present invention is described in further detail and completely. The embodiments described below are exemplary only for explaining the present invention and should not be construed as limiting the present invention.

[0052] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples were purchased from the market unless otherwise specified.

[0053] The RSVM2 gene is located between the F and L genes and contains two open reading frames, M2-1 and M2-2. The full length of the M2-1 gene is about 826 nucleotides, encoding 195 amino acids, located at the 5' end of the M2 gene, and its 3' end overlaps with the head of the M2-2 gene. M2-1 is the envelope and capsid of the RSV virus Components, together with the N and P proteins, constitute the viral capsid.

[0054] 1. Cloning and prokaryotic expression of M2-1-NP fusion protein

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a seasonal influenza-RSV combined vaccine and a preparation method and application thereof. The combined vaccine comprises a seasonal influenza virus protein and respiratory syncytial virus (RSV) fusion protein and an immunologic adjuvant. The fusion protein is a highly conserved protein sequence of seasonal influenza viruses and RSVs. The constructed fusion protein and theimmunologic adjuvant are mixed according to a ratio of (0.5-2): 1 so that the seasonal influenza-RSV combined vaccine is obtained. The recombinant fusion protein is used as a novel antigen and increases serum IgG and mucosal system IgA antibody titer through oral and nasal administration. The combined vaccine can cause common immune response to seasonal influenza viruses and RSVs. Through use ofthe mucosal adjuvant, the mucosal immune is produced and the immune effects are improved.

Description

technical field [0001] The invention relates to a seasonal influenza-RSV combined vaccine and its preparation method and application, belonging to the field of biotechnology. Background technique [0002] 1. Pathogenic microorganisms and vaccines [0003] Microorganisms that can cause infectious diseases in humans or animals are called pathogenic microorganisms or pathogenic microorganisms. Infection refers to the process of pathogenic microorganisms invading the body, growing and multiplying in certain parts, and causing a series of pathophysiological processes. When pathogenic microorganisms invade the body, the pathogenic microorganisms interact with the body and change each other's activity and function. Therefore, whether they can cause infectious diseases depends on the pathogenicity or virulence of the pathogenic microorganisms on the one hand, and on the other hand. Depends on the body's resistance, that is, immunity. The ability of pathogenic bacteria to cause in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/155A61K39/145A61K39/39A61P31/14A61P31/16C07K19/00C12N15/62C12N15/70
CPCA61K39/12A61K39/39A61K2039/542A61K2039/543A61K2039/55544A61K2039/55566A61K2039/70C07K14/005C12N2760/16122C12N2760/16134C12N2760/18522C12N2760/18534
Inventor 吴克闫利明刘昊智王文灏
Owner BRAVOVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap